by Gordon Hensley | Feb 10, 2026 | advocacy, Business, Communications, health care, lobbying, Media Relations |
I didn’t see firsthand how the K Street lobbying scene worked until the tail-end of my 30s and a little voice in my head said it was time to become an adult — or at least more of an adult. I was having the time of my life going through a revolving door I...
by Gordon Hensley | Jun 9, 2025 | advocacy, Business, Communications, lobbying, Media Relations, state government, U.S. House, U.S. Senate |
From PR Week and PR Daily to Gotham Ghostwriters and Axios the demise of op-eds as a content-sharing vehicle is a discussion worth having. And per usual, those proclaiming simply “Yes” and “No” are wrong. The real answer is “No —...
by Gordon Hensley | May 10, 2024 | advocacy, Business, Communications, GOP Politics, lobbying, U.S. House, U.S. Senate |
It’s been almost 40 years since then-Wall Street Journal stars Jeff Birnbaum and Alan Murray wrote their seminal 1987 masterpiece Showdown at Gucci Gulch detailing passage of the Tax Reform Act of 1986 — the single most sweeping U.S. tax...
by Gordon Hensley | Apr 11, 2020 | advocacy, Business, lobbying, polling
With the onset of the COVID-19 pandemic, DC consultants, lobbyists, data specialists and others are scrambling for their lives, and indeed, their very livelihoods. Clients representing both vast sectors as well as smaller sub-sectors of the U.S. economy are shelling...
by Gordon Hensley | Mar 26, 2019 | advocacy, Business, GOP Politics, health care, lobbying, Pharmaceutical
This more of an addenda to my last post noting how PBMs have, to their detriment, ended up on Sen. Grassley’s radar screen. Now Sen. John Cornyn (R-TX), up for reelection this cycle, has weighed in: “The whole rebate thing just looks kind of — well...
by Gordon Hensley | Feb 21, 2019 | advocacy, Business, CMS, health care, lobbying, Medicare Cuts, Pharma, U.S. House, U.S. Senate
Among the most complex but significant issues in the unfolding debate about prescription drug pricing reform is pharmacy benefit manager (PBM) rebates — or, so-called “rebates” — as many objective observers see them as kickbacks or opaque...
